<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850057</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD-060201</org_study_id>
    <nct_id>NCT00850057</nct_id>
    <nct_alias>NCT00783874</nct_alias>
  </id_info>
  <brief_title>Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)</brief_title>
  <official_title>A Phase 1, Open Label, Dose-escalation, Pharmacodynamic Study of Intranodal Injection of Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memgen, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives&#xD;
&#xD;
        -  To determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35)&#xD;
           when it is injected directly into the lymph nodes of patients with CLL or SLL.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  To determine and monitor clinical and biological responses in patients treated with&#xD;
           injections of Ad-ISF35.&#xD;
&#xD;
        -  To determine how ISF35 works in CLL/SLL patients' cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35) when injected directly into lymph nodes of patients with CLL/SLL.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine and monitor clinical and biological responses in patients treated with intranodal injections of Ad-ISF35.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine pharmacodynamic (PD) parameters in patients treated with intranodal injections of ISF35.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intranodal injection of Ad-ISF35</intervention_name>
    <description>Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of B-cell CLL/SLL including&#xD;
&#xD;
               -  Lymphocytosis of monoclonal B-cells co-expressing ≥ one B-cell marker (CD19,&#xD;
                  CD20, or CD23) and CD5 in peripheral blood or lymph node AND&#xD;
&#xD;
               -  Bone marrow with ≥ 30% mononuclear cells having the CLL/SLL phenotype.&#xD;
&#xD;
          2. Presence of at least ONE single accessible AND palpable lymph node in the cervical,&#xD;
             supraclavicular, axillary, or inguinal regions. The size of the lymph nodes must be&#xD;
             larger than 2x2 cm in the horizontal and perpendicular axes.&#xD;
&#xD;
          3. Intermediate or High risk, poor prognosis CLL/SLL&#xD;
&#xD;
          4. Indication for treatment as defined by the NCI Working Group Guidelines:&#xD;
&#xD;
               -  Massive (i.e. &gt; 6 cm below the left costal margin) or progressive splenomegaly OR&#xD;
&#xD;
               -  Massive lymph nodes or nodal clusters (i.e. &gt; 10 cm in longest diameter), or&#xD;
                  progressive lymphadenopathy OR&#xD;
&#xD;
               -  Grade 2 or 3 fatigue OR&#xD;
&#xD;
               -  Fever ≥ 100.5˚F or night sweats for greater than 2 weeks without documented&#xD;
                  infection OR&#xD;
&#xD;
               -  Presence of weight loss ≥ 10% over the preceding 6 months OR&#xD;
&#xD;
               -  Progressive lymphocytosis with an increase of ≥ 50% over a 2-month period or an&#xD;
                  anticipated doubling time of less than 6 months.&#xD;
&#xD;
               -  Evidence of progressive marrow failure as manifested by the development of, or&#xD;
                  worsening of, anemia and / or thrombocytopenia.&#xD;
&#xD;
               -  Autoimmune anemia and / or thrombocytopenia poorly responsive to corticosteroid&#xD;
                  therapy.&#xD;
&#xD;
          5. Males and females 18 years of age and older&#xD;
&#xD;
          6. Laboratory parameters as specified below:&#xD;
&#xD;
               -  Hematologic: Hemoglobin ≥ 10 g/dL (may be post-transfusion); platelet count ≥ 50&#xD;
                  x103/mm3&#xD;
&#xD;
               -  Hepatic: Total Bilirubin &lt; 2 X ULN, and ALT and AST &lt; 2 x ULN&#xD;
&#xD;
               -  Renal: Creatinine ≤ 2 X ULN&#xD;
&#xD;
          7. ECOG Performance Status ≤ 2&#xD;
&#xD;
          8. Anticipated survival of at least 3 months&#xD;
&#xD;
          9. For men and women of child-producing potential, use of effective barrier contraceptive&#xD;
             methods during the study and for one month following treatment.&#xD;
&#xD;
         10. Ability to understand the requirements of the study, provide written informed consent&#xD;
             and authorization of use and disclosure of protected health information, and agree to&#xD;
             abide by the study restrictions and return for the required assessments.&#xD;
&#xD;
         11. Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2,&#xD;
             hepatitis A, B, C within 30 days of registration. (Antibody, antigen and nucleic acid&#xD;
             tests acceptable, depending on institutional standards.).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing women&#xD;
&#xD;
          2. Treatment with chemotherapy or monoclonal antibody within 28 days prior to entering&#xD;
             the study.&#xD;
&#xD;
          3. Treatment with chemotherapy or monoclonal antibody during the time of participation in&#xD;
             this trial.&#xD;
&#xD;
          4. Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional&#xD;
             Classification&#xD;
&#xD;
          5. Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of&#xD;
             breath, COPD)&#xD;
&#xD;
          6. Participation in any investigational drug study within 28 days prior to ISF35&#xD;
             administration. (Patient must have recovered from all acute effects of previously&#xD;
             administered investigational agents)&#xD;
&#xD;
          7. History of malignancy other than CLL within five years of registration, except&#xD;
             patients with adequately treated basal, squamous cell carcinoma or localized cervical&#xD;
             cancer.&#xD;
&#xD;
          8. Active symptomatic fungal, bacterial and/or viral infection including active HIV or&#xD;
             viral (A, B or C) hepatitis.&#xD;
&#xD;
          9. Any illness or condition that in the opinion of the Investigator may affect safety of&#xD;
             treatment or evaluation of any the study's endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Januario Castro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Clinical Professor in the Blood and Marrow Transplantation Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

